CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2008-11-06): Etravirine does not appear to be hepatotoxic

Clinical

Etravirine does not appear to be hepatotoxic

Last Updated: 2008-11-06 14:11:40 -0400 (Reuters Health)

SAN FRANCISCO (Reuters Health) - Longer term follow-up of the recently approved non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (Intelence; Tibotec Therapeutics) for the treatment of HIV infection shows that etravirine does not appear to cause elevations in serum alanine transaminase levels (ALT) or other signs of hepatotoxicity, researchers announced here at the annual meeting of the American Association for the Study of Liver Diseases.

Other NNRTIs, in particular nevirapine, have been associated with significant liver toxicity, said principal investigator Dr. Jacob Lalezari of Quest Clinical Research in San Francisco, California, as he presented results of a pooled analysis of the DUET-1 and DUET-2 trials.

FDA approved etravirine in January as a component of HIV therapy that includes a protease inhibitor, based largely on the results of DUET-1 and DUET-2.

Dr. Lalezari presented the 48-week data on etravirine's effect on liver function in 599 patients in DUET-1 and 604 patients in DUET-2 who were randomized to either etravirine or placebo in addition to combination therapy that included a protease inhibitor. Patients were treatment-experienced and two-thirds had two or more resistance mutations to other NNRTIs and/or protease inhibitors.

Overall adverse events "were not different between the etravirine and placebo arms of the study," with the exception of rash with the NNRTI. After a median of 52 weeks of treatment, there were 39 events in the etravirine arm and 37 in the placebo arm.

Elevations in liver enzymes were rare and "evenly split between the arms and generally asymptomatic regardless of regimen," Dr. Lalezari reported.

Among the 139 patients co-infected with hepatitis B or C, there were four treatment-related hepatic adverse events in patients receiving etravirine and three such events in patients on placebo, which "were likely attributable to hepatitis" itself.

"The appropriate patient profile is still emerging" for treatment with etravirine, but the lack of hepatotoxicity "is one less thing to worry about," Dr. Lalezari said after presenting his findings.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.